Harpoon Therapeutics appoints Haibo Wang as SVP of business development

Harpoon Therapeutics introduced Haibo Wang as its SVP of small business development this 7 days.

Wang, who joins Harpoon from Hummingbird Bioscience, has a qualifications of 15 a long time in biopharma business enterprise enhancement and finance, as properly as mergers and acquisitions.

At Hummingbird, Wang was VP of organization advancement. Prior to that, he served as director of organization progress at Amgen and served facilitate the company’s acquisitions of Teneobio and Five Key Therapeutics. Wang also aided strike scientific collaborations for Amgen’s most cancers pipeline, such as 1 with biotech BeiGene.

Wang’s occupation also features time used as a mergers and acquisitions marketing consultant at Deloitte.

“We are pleased to welcome Haibo as senior vice president of enterprise growth at Harpoon,” Julie Eastland, president and CEO of Harpoon Therapeutics, reported in a assertion. “Haibo’s extensive experience and strategic acumen will play a pivotal job in driving our business enterprise progress and forging impactful partnerships.”

Harpoon, which focuses on immunotherapies for most cancers, is now building T mobile engagers that trigger a patient’s T cells to target specified antigen-expressing cells, using its platform, Tri-precise T cell Activating Construct (TriTAC).

In March 2022, the pharma made the decision to discontinue its after-primary applicant for prostate most cancers and invest in other therapies. 

Its pipeline at the moment consists of 3 immunotherapies presently in Stage 1 trials – HPN328 (DLL3) for compact cell lung cancer, HPN217 (BCMA) for multiple myeloma, and HPN536 for ovarian cancer and other stable tumors. Harpoon is also executing preclinical work on 4 other therapies, together with a person in gastrointestinal cancers.

In April, Harpoon presented preclinical benefits on equally HPN217 and HPN328, saying the latter had “potential for long-phrase anti-tumor immunity and sturdy responses in individuals.”

“With our Stage 1 trial ongoing and further more reports prepared, we glance forward to continuing our medical enhancement efforts for these two promising packages,” Luke Walker, Harpoon’s chief healthcare officer, stated in a assertion at the time.

At the finish of June, the company introduced it completed client enrollment for its Period 1 dose escalation demo for HPN217, noting that it was “an important move toward probably bringing this treatment to individuals with highly developed illness who have progressed following prior solutions.”

Eastland famous that Wang’s appointment to SVP of small business progress will be a portion of the company’s efforts to transfer HPN217 and HPN328 into enhancement.

“We are confident that [Wang’s] knowledge and being familiar with of targets such as BCMA and DLL3 will lead substantially to our mission to remodel most cancers cure as a result of the electric power of T cell engagers,” Eastland included.

Related posts